Mexico's methamphetamine precursor chemical interventions: impacts on drug treatment admissions

James K Cunningham1, Ietza Bojorquez, Octavio Campollo

  • 1Department of Family and Community Medicine, The University of Arizona, 1450 N. Cherry Avenue, Tucson, AZ 85719, USA. jkcunnin@email.arizona.edu

Abstract

Insights

Mexico’s interventions targeting methamphetamine precursor chemicals, pseudoephedrine and ephedrine, significantly reduced drug treatment admissions. These precursor chemical controls show positive impacts domestically and in Texas, suggesting sustained effects across North America.

Area of Science:

  • Public Health
  • Criminology
  • Substance Abuse Research

Background:

  • Methamphetamine use poses significant public health challenges.
  • Mexico has implemented precursor chemical control strategies to combat illicit methamphetamine production.
  • Pseudoephedrine and ephedrine are key precursor chemicals for methamphetamine synthesis.

Purpose of the Study:

  • To evaluate the impact of Mexican precursor chemical interventions on methamphetamine treatment admissions.
  • To assess the effectiveness of these policies as an indicator of reduced methamphetamine consequences.

Main Methods:

  • A quasi-experimental design using autoregressive integrated moving average (ARIMA)-based intervention time-series analysis.
  • Analysis of monthly treatment admissions for methamphetamine and control substances (cocaine, heroin, alcohol) in Mexico and Texas from 1996 to 2008.
  • Examination of interventions including precursor chemical restrictions (2005), a major company closure (2007), and a precursor ban (2008).

Main Results:

  • Precursor chemical restrictions were associated with temporary decreases in methamphetamine treatment admissions (12% in Mexico, 11% in Texas).
  • The closure of a major precursor chemical company led to substantial and sustained decreases (56% in Mexico, 48% in Texas).
  • No significant changes were observed in control substance treatment admissions, indicating policy specificity.

Conclusions:

  • Mexico's precursor chemical interventions demonstrated positive impacts on methamphetamine treatment admissions within Mexico and Texas.
  • These findings suggest that coordinated precursor control efforts across North America can effectively reduce the consequences of illicit drug production.
  • The study highlights the potential for sustained positive impacts from these drug policy interventions.

Related Concept Videos

Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...